Cited by 604Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Open access

Sabri, Osama, Sabbagh, Marwan N., Seibyl, John, Barthel, Henryk, Akatsu, Hiroyasu, Ouchi, Yasuomi, Senda, Kohei, Murayama, Shigeo, Ishii, Kenji, Takao, Masaki, Beach, Thomas G., Rowe, Christopher C., Leverenz, James B., Ghetti, Bernardino, Ironside, James W., Catafau, Ana M., Stephens, Andrew W., Mueller, Andre, Koglin, Norman, Hoffmann, Anja, Roth, Katrin, Reininger, Cornelia, Schulz‐Schaeffer, Walter J., Florbetaben Phase 3 Study Group·2015·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2015.02.004

Open this paper in CoChat — free account Open PDF

Abstract

Background: Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods: Open‐label, nonrandomized, multicenter, phase 3 study to validate the 18 F‐labeled β‐amyloid tracer florbetaben by comparing in vivo PET imaging with post‐mortem histopathology. Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty‐six of 47 neuritic β‐amyloid‐positive cases were read as PET positive, and 24 of 27 neuritic β‐amyloid plaque‐negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue‐scan matched analysis was performed. In areas known to strongly accumulate β‐amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology‐confirmed neuritic β‐amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. Trial registration: ClinicalTrials.gov NCT01020838 .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2015.02.004

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“Middle frontal gyrus Intense [19] 18/21 (85.”
Influential
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 9,034
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citation
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citation
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
Scheltens, P., Leys, D., Barkhof, F., Huglo, D. G., Weinstein, H. C., Vermersch, P., Kuiper, M. A., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,811
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117

Show all 33 references

Sorted by citations

Items 101–200 of 604

A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 68
An intelligent Alzheimer’s disease diagnosis method using unsupervised feature learning
Razavi, F., Tarokh, M. J., & Alborzi, M. (2019) · Journal Of Big Data · doi:10.1186/s40537-019-0190-7 · Cited by 61
Early detection of amyloid load using 18F-florbetaben PET
Bullich, S., Roé-Vellvé, N., Marquié, M., Landau, S. M., Barthel, H., Villemagne, V. L., Sanabria, Á., Tartari, J. P., Sotolongo-Grau, O., Doré, V., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00807-6 · Cited by 71
Self-citation
Amyloid imaging for dementia in clinical practice
O'Brien, J. T., & Herholz, K. (2015) · BMC Medicine · doi:10.1186/s12916-015-0404-6 · Cited by 57
Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia: A Systematic Review
Fink, H. A., Linskens, E. J., Silverman, P. C., McCarten, J. R., Hemmy, L. S., Ouellette, J. M., Greer, N. L., Wilt, T. J., & Butler, M. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3888 · Cited by 57
In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice
Ni, R., Villois, A., Deán‐Ben, X. L., Chen, Z., Vaas, M., Stavrakis, S., Shi, G., deMello, A. J., Ran, C., Razansky, D., et al. (2021) · Photoacoustics · doi:10.1016/j.pacs.2021.100285 · Cited by 55
Added value of 18 F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study
Ceccaldi, M. P., Jonveaux, T., Verger, A., Krolak‐Salmon, P., Houzard, C., Godefroy, O., Shields, T., Perrotin, A., Gismondi, R., Bullich, S., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.009 · Cited by 56
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care
Dickerson, B. C., Atri, A., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14337 · Cited by 62
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease
Ikonomović, M. D., Buckley, C. J., Abrahamson, E. E., Kofler, J., Mathis, C. A., Klunk, W. E., & Farrar, G. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02175-1 · Cited by 58
Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
Thal, D. R., Beach, T. G., Zanette, M., Lilja, J., Heurling, K., Chakrabarty, A., Ismail, A., Farrar, G., Buckley, C. J., & Smith, A. P. L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1897-9 · Cited by 58
Self-citation
AMYPAD Diagnostic and Patient Management Study: Rationale and design
Frisoni, G. B., Barkhof, F., Altomare, D., Berkhof, J. H., Boccardi, M., Canzoneri, E., Collij, L. E., Drzezga, A. E., Farrar, G., Garibotto, V., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.003 · Cited by 53
Self-citation
Molecular Tools to Detect Alloforms of Aβ and Tau: Implications for Multiplexing and Multimodal Diagnosis of Alzheimer’s Disease
Arora, H., Ramesh, M., Rajasekhar, K., & Govindaraju, T. (2020) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20190356 · Cited by 53
Imaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S. G., & Rosa‐Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 57
Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis
Matías‐Guiu, J. A., Pytel, V., Cabrera‐Martín, M. N., Galán, L., Valles‐Salgado, M., Guerrero, A., Moreno‐Ramos, T., Matías‐Guiu, J., & Carreras, J. L. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3434-1 · Cited by 51
Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production
Yan, L., Deng, Y., Gao, J., Liu, Y., Li, F., Shi, J., & Gong, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00106 · Cited by 50
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 52
Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients
Carswell, C. J., Win, Z., Muckle, K., Kennedy, A. M., Waldman, A. D., Dawe, G., Barwick, T. D., Khan, S., Malhotra, P., & Perry, R. J. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316194 · Cited by 50
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A. K., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 56
Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
Mihaescu, A. S., Valli, M., Uribe, C., Díez‐Cirarda, M., Masellis, M., Graff‐Guerrero, A., & Strafella, A. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00964-1 · Cited by 53
Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification
Bollack, A., Pemberton, H., Collij, L. E., Markiewicz, P. J., Cash, D. M., Farrar, G., & Barkhof, F. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13158 · Cited by 51
Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer’s disease from tear fluid
Lee, S., Kim, E., Moon, C., Park, C., Lim, J.-W., Baek, M. S., Shin, M., Ki, J., Cho, H., Ji, Y. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43995-5 · Cited by 50
Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers
Bensaïdane, M. R., Beauregard, J., Poulin, S. P., Buteau, F.-A., Guimond, J. V., Bergeron, D., Verret, L., Fortin, M., Houde, M., Bouchard, R. W., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151180 · Cited by 50
Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology
Beach, T. G., Thal, D. R., Zanette, M., Smith, A. P. L., & Buckley, C. J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150732 · Cited by 48
Self-citation
Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer’s disease
Damar, U., Gersner, R., Johnstone, J. T., Schachter, S. C., & Rotenberg, A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.12.006 · Cited by 49
Patient and caregiver reactions to clinical amyloid imaging
Grill, J. D., Cox, C. G., Kremen, S. A., Mendez, M. F., Teng, E., Shapira, J. S., Ringman, J. M., & Apostolova, L. G. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.001 · Cited by 48
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 48
Self-citation
Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid
Cho, S. H., Choe, Y. S., Park, S., Kim, Y. J., Kim, H. J., Jang, H., Kim, S. J., Kim, J. P., Jung, Y. H., Kim, B. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70978-z · Cited by 47
The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort
Touroutoglou, A., Katsumi, Y., Brickhouse, M. J., Zaitsev, A., Eckbo, R., Aisen, P. S. S., Beckett, L. A., Dage, J. L., Eloyan, A., Foroud, T., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13466 · Cited by 47
Self-citation
A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?
Beach, T. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0072-x · Cited by 50
Self-citation
Quantitative Susceptibility Mapping of Amyloid-β Aggregates in Alzheimer’s Disease with 7T MR
Tiepolt, S., Bank, N. B., Andreas Schäfer, A., Rullmann, M., Roggenhofer, E., Gertz, H., Schroeter, M. L., Patt, M., Bazin, P., Jochimsen, T. H., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180118 · Cited by 47
Self-citation
Deep learning-based amyloid PET positivity classification model in the Alzheimer’s disease continuum by using 2-[18F]FDG PET
Kim, S. H., Lee, P., Oh, K. T., Byun, M. S., Yi, D., Lee, J. H., Kim, Y. K., Ye, B. S., Yun, M., Lee, D. Y., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00798-3 · Cited by 45
Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods
Jovalekic, A., Roé-Vellvé, N., Koglin, N., Lagos‐Quintana, M., Nelson, A. S., Diemling, M., Lilja, J., Gómez-González, J. P., Doré, V., Bourgeat, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06279-0 · Cited by 47
Self-citation
Amyloid Imaging: Poised for Integration into Medical Practice
Anand, K., & Sabbagh, M. N. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0474-y · Cited by 46
Self-citation
Neuropathological correlates of amyloid PET imaging in Down syndrome
Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomović, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 46
Amyloid PET imaging in clinical practice
Kolanko, M., Win, Z., Loreto, F., Patel, N., Carswell, C. J., Gontsarova, A., Perry, R. J., & Malhotra, P. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 47
In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
Ni, R., Röjdner, J., Voytenko, L. P., Dyrks, T., Thiele, A., Marutle, A., & Nordberg, A. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201344 · Cited by 42
Tenascin-C Is Associated with Cored Amyloid-β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly
Mi, Z., Halfter, W. M., Abrahamson, E. E., Klunk, W. E., Mathis, C. A., Mufson, E. J., & Ikonomović, M. D. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw062 · Cited by 43
18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
Martínez, G., Vernooij, R. W. M., Padilla, P. F., Zamora, J., Flicker, L. A., & Bonfill, X. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012883 · Cited by 44
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00653-x · Cited by 44
Self-citation
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 42
Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol
Bullich, S., Barthel, H., Koglin, N., Becker, G., Santi, S. D., Jovalekic, A., Stephens, A. W., & Sabri, O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200964 · Cited by 42
Self-citation
Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 44
Self-citation
Current radiotracers to image neurodegenerative diseases
Tiepolt, S., Patt, M., Aghakhanyan, G., Meyer, P., Hesse, S., Barthel, H., & Sabri, O. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0070-7 · Cited by 46
Self-citation
Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia
Lee, Y. H., Bak, Y., Park, C.-H., Chung, S. J., Yoo, H. S., Baik, K., Jung, J. H., Sohn, Y. H., Shin, N., & Lee, P. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.021 · Cited by 41
Deep learning for Alzheimer's disease: Mapping large-scale histological tau protein for neuroimaging biomarker validation
Ushizima, D. M., Chen, Y., Alegro, M., Ovando, D., Eser, R. A., Lee, W., Poon, K., Shankar, A., Kantamneni, N., Satrawada, S., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118790 · Cited by 45
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 43
Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care
Apostolova, L. G., Haider, J. M., Goukasian, N., Rabinovici, G. D., Chételat, G., Ringman, J. M., Kremen, S. A., Grill, J. D., Restrepo, L., Mendez, M. F., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.001 · Cited by 39
Non-Invasive RF Technique for Detecting Different Stages of Alzheimer’s Disease and Imaging Beta-Amyloid Plaques and Tau Tangles in the Brain
Saied, I., Arslan, T., Chandran, S., Smith, C., Spires‐Jones, T. L., & Pal, S. (2020) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2020.3011359 · Cited by 44
A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-β PET Scans
Tahmi, M., Bou-Zeid, W., & Razlighi, Q. R. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.228510 · Cited by 38
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: From biological biomarkers to clinical syndromes
Carandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36
Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01296-5 · Cited by 39
Automatic offline-capable smartphone paper-based microfluidic device for efficient biomarker detection of Alzheimer's disease
Duan, S., Cai, T., Liu, F., Li, Y., Yuan, H., Yuan, W., Huang, K., Hoettges, K. F., Chen, M., Lim, E. G., et al. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342575 · Cited by 37
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria
Grundman, M., Johnson, K. A., Lu, M., Siderowf, A. D., Dell’Agnello, G., Arora, A., Skovronsky, D., Mintun, M. A., Pontecorvo, M. J., & for the 18F-AV-45-A17 Study Group (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000441139 · Cited by 38
Self-citation
Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review
Ulanova, M., Poljak, A., Wen, W. X., Bongers, A., Gloag, L., Gooding, J. J., Tilley, R. D., Sachdev, P. S., & Braidy, N. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0316 · Cited by 39
Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease
Baek, M. S., Cho, H., Lee, H. S., Choi, J. Y., Lee, J., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04773-3 · Cited by 37
Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort
Reimand, J., Boon, B. D. C., Collij, L. E., Teunissen, C. E., Rozemüller, A. J. M., van Berckel, B. N. M., Scheltens, P., Ossenkoppele, R., & Bouwman, F. H. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51195 · Cited by 40
Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia
Mashima, K., Ito, D., Kameyama, M., Osada, T., Tabuchi, H., Nihei, Y., Yoshizaki, T., Noguchi, E., Tanikawa, M., Iizuka, T., et al. (2017) · European Neurology · doi:10.1159/000464322 · Cited by 38
Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada
Laforce, R. J., Rosa‐Neto, P., Soucy, J., Rabinovici, G. D., Dubois, B., & Gauthier, S. G. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.401 · Cited by 34
Resource Use and Cost of Alzheimer’s Disease in France: 18-Month Results from the GERAS Observational Study
Rapp, T., Andrieu, S., Chartier, F., Deberdt, W. G., Reed, C. C., Belger, M. A., & Vellas, B. J. (2017) · Value in Health · doi:10.1016/j.jval.2017.09.019 · Cited by 35
Amyloid-β-related and unrelated cortical thinning in dementia with Lewy bodies
Lee, Y., Jeon, S., Yoo, H. S., Chung, S. J., Lee, S., Lee, P. H., Sohn, Y. H., Yun, M., Evans, A. C., & Ye, B. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.007 · Cited by 35
Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects
Li, J., Liao, W., Huang, D., Ou, M., Chen, T., Wang, X., Zhao, R., Zhang, L., Mei, L., Liu, J., et al. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215375 · Cited by 37
[18F]Florbetaben: A Review in β-Amyloid PET Imaging in Cognitive Impairment
Syed, Y. Y., & Deeks, E. D. (2015) · CNS Drugs · doi:10.1007/s40263-015-0258-7 · Cited by 34
Evidence-based Interpretation of Amyloid-β PET Results
Bergeron, D., Ossenkoppele, R., & Laforce, R. J. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000239 · Cited by 33
Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments
Cho, S. H., Choe, Y. S., Kim, Y. J., Lee, B., Kim, H. J., Jang, H., Kim, J. P., Jung, Y. H., Kim, S.-J., Kim, B. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76102-5 · Cited by 34
A History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 37
Self-citation
The ADNI PET core at 20
Jagust, W. J., Koeppe, R. A., Rabinovici, G. D., Villemagne, V. L., Harrison, T. M., Landau, S. M., & Initiative, T. A. D. N. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14165 · Cited by 34
Liquid-liquid phase separation in Alzheimer’s disease
Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02407-3 · Cited by 33
Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimer’s disease
DeBay, D. R., Reid, G. A., Macdonald, I. R., Mawko, G., Burrell, S., Martin, E. V., Bowen, C. V., & Darvesh, S. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.009 · Cited by 33
Clinical Phenotypes in Corticobasal Syndrome with or without Amyloidosis Biomarkers
Benvenutto, A., Guedj, É., Félician, O., Eusébio, A., Azulay, J., Ceccaldi, M. P., & Koric, L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190961 · Cited by 34
Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 35
A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date
Lee, B. G., Leavitt, M. J., Bernick, C. B., Léger, G. C., Rabinovici, G. D., & Banks, S. J. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5558 · Cited by 34
Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification
Presotto, L., Iaccarino, L., Sala, A., Vanoli, E. G., Muscio, C., Nigri, A., Bruzzone, M. G., Tagliavini, F., Gianolli, L., Perani, D., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.07.013 · Cited by 33
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study
Sakr, F. A., Grothe, M. J., Cavedo, E., Jelistratova, I., Habert, M., Dyrba, M., González‐Escamilla, G., Bertin, H., Locatelli, M., Lehéricy, S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0466-3 · Cited by 32
Self-citation
Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer’s Disease to Parkinson’s Disease
Weinshel, S., Irwin, D. J., Zhang, P., Weintraub, D. A., Shaw, L. M. J., Siderowf, A. D., & Xie, S. X. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-212989 · Cited by 32
Anomaly Analysis of Alzheimer’s Disease in PET Images Using an Unsupervised Adversarial Deep Learning Model
Baydargil, H. B., Park, J.-S., & Kang, D.-Y. (2021) · Applied Sciences · doi:10.3390/app11052187 · Cited by 30
Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer’s disease：a systematic review with meta-analysis
Cheng, L., Li, W., Chen, Y., Lin, Y., Wang, B., Guo, Q., & Miao, Y. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327864 · Cited by 36
β-Amyloid Biomarker Detection for Alzheimer’s Disease
Li, C.-Z., Grajales, S. A., Shuang, S., Dong, C., & Nair, M. G. (2017) · Journal of Analysis and Testing · doi:10.1007/s41664-017-0014-8 · Cited by 31
Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment
Giacomucci, G., Mazzeo, S., Crucitti, C., Ingannato, A., Bagnoli, S., Padiglioni, S., Galdo, G., Emiliani, F., Frigerio, D., Moschini, V., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120805 · Cited by 31
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0561-5 · Cited by 31
Styryl Group, a Friend or Foe in Medicinal Chemistry
Bhurta, D., & Bharate, S. B. (2022) · ChemMedChem · doi:10.1002/cmdc.202100706 · Cited by 31
Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia
Ricci, M., Cimini, A., Chiaravalloti, A., Filippi, L., & Schillaci, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207481 · Cited by 33
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease
Shirvan, J. C., Clement, N. F., Ye, R., Katz, S. R., Schultz, A. P., Johnson, K. A., Gómez‐Isla, T., Frosch, M. P., Growdon, J. H., & Gomperts, S. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007855 · Cited by 31
Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease
Ramusino, M. C., Garibotto, V., Bacchin, R. A., Altomare, D., Dodich, A., Assal, F., Mendes, A., Costa, A. C., Tinazzi, M., Morbelli, S. D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04466-6 · Cited by 29
Relationship Between Thyroid Hormone Levels and the Pathology of Alzheimer's Disease in Euthyroid Subjects
Choi, B. W., Kim, S., Kang, S., Won, K. S., Yi, H., & Kim, H. W. (2020) · Thyroid · doi:10.1089/thy.2019.0727 · Cited by 29
Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment
Jeong, S. H., Kim, H. R., Kim, J., Kim, H., Hong, N., Jung, J. H., Baik, K., Cho, H., Lyoo, C. H., Ye, B. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012534 · Cited by 32
Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
Ni, R., & Nitsch, R. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.751897 · Cited by 30
PET/CT of Dementia
Zukotynski, K., Kuo, P. H., Mikulis, D. J., Rosa‐Neto, P., Strafella, A. P., Subramaniam, R. M., & Black, S. E. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19822 · Cited by 31
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable
Farrar, G., Weber, C. J., & Rabinovici, G. D. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100008 · Cited by 27
Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk
Ott, B. R., Jones, R. N., Noto, R. B., Yoo, D. C., Snyder, P. J., Bernier, J. N., Carr, D. B., & Roe, C. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.10.008 · Cited by 30
Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort
Kubota, M., Bun, S., Takahata, K., Kurose, S., Momota, Y., Iwabuchi, Y., Tezuka, T., Tabuchi, H., Seki, M., Yamamoto, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01778-8 · Cited by 34
Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets
Herman, F. J., Simkovic, S. J., & Pasinetti, G. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14569 · Cited by 29
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 27
Self-citation
Visualizing Aβ deposits in live young AD model mice with a simple red/near-infrared-fluorescent AIEgen
Wang, Y., Mei, D., Zhang, X., Qu, D., Mei, J., & Tian, H. (2021) · Science China Chemistry · doi:10.1007/s11426-021-1113-0 · Cited by 27
Vanillin Benzothiazole Derivative Reduces Cellular Reactive Oxygen Species and Detects Amyloid Fibrillar Aggregates in Alzheimer’s Disease Brain
Gharai, P. K., Khan, J., Mallesh, R., Garg, S., Saha, A., Ghosh, S., & Ghosh, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00771 · Cited by 28
Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease
DeBay, D. R., Reid, G. A., Pottie, I. R., Martin, E. V., Bowen, C. V., & Darvesh, S. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.01.005 · Cited by 27
FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Kepp, K. P., Castellani, R. J., Perry, G. L., Alavi, A. A., & Barrio, J. R. (2023) · Diagnostics · doi:10.3390/diagnostics13132254 · Cited by 28
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 26

Authors: Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., Beach, T. G., Rowe, C. C., Leverenz, J. B., Ghetti, B., Ironside, J. W., Catafau, A. M., Stephens, A. W., Mueller, A., Koglin, N., Hoffmann, A., Roth, K., Reininger, C., Schulz‐Schaeffer, W. J., & Florbetaben Phase 3 Study Group
Affiliations: University Hospital Leipzig (DE)
Banner Sun Health Research Institute (US)
Molecular Neuroimaging LLC New Haven CT USA
Nagoya City University (JP)
Hamamatsu University (JP)
Koseikai Hospital Toyohashi Japan
Tokyo Metropolitan Institute of Gerontology (JP)
Institute of Brain and Blood Vessels (JP)
The University of Melbourne (AU)
University of Washington (US)
Indiana University Indianapolis (US)
University of Edinburgh (GB)
Piramal (Germany) (DE)
Piramal Imaging GmbH Berlin Germany
Bayer (Germany) (DE)
Universitätsmedizin Göttingen (DE)
Corresponding author: Sabri, Osama
ORCID: Sabri, Osama
Sabbagh, Marwan N.
Seibyl, John
Barthel, Henryk
Akatsu, Hiroyasu
Ouchi, Yasuomi
Murayama, Shigeo
Ishii, Kenji
Takao, Masaki
Beach, Thomas G.
Rowe, Christopher C.
Leverenz, James B.
Ghetti, Bernardino
Ironside, James W.
Stephens, Andrew W.
Koglin, Norman
Roth, Katrin
Schulz‐Schaeffer, Walter J.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2015-03-27
Volume: 11
Issue: 8
Pages: 964-974
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2015.02.004
OpenAlex: W2169508236
Cited by: 602
References: 33
Citations by year: 2026: 57 · 2025: 64 · 2024: 59 · 2023: 50 · 2022: 56 · 2021: 64 · 2020: 61 · 2019: 46 · 2018: 42 · 2017: 47 · 2016: 42 · 2015: 13
FWCI: 39.00
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
GRO (submittedVersion)
Funders: Bioscript Medical
Piramal Imaging S.A
Bayer Pharma AG
Piramal Imaging S.A.
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: florbetaben, amyloid PET
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Aniline Compounds, Brain, Diagnosis, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Psychiatric Status Rating Scales, Radiography, ROC Curve, Stilbenes, Cohort Studies, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks